News >

ER Modulation May Overcome AI Resistance in ESR1-Mutant Breast Cancer

Caroline Seymour
Published: Friday, Dec 06, 2019

Hope Rugo, MD

Hope Rugo, MD

Resistance to aromatase inhibitors (AIs) is a growing concern in patients with advanced hormone receptor (HR)–positive, HER2-negative breast cancer, said Hope S. Rugo, MD, FASCO, who added that although fulvestrant (Faslodex) has shown some activity in patients who develop ESR1 mutations, more effective treatment options are needed.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication